Cell Therapy News/Articles, page-17701

Nice one Wilbs

As opposed to the 2nd study of Kurtzberg
et al. (42), patient population in our study were highly pretreated and
refractory to previous treatments, which might have worsened
response.Some authors (42, 44, 49) have also showed that, when
MSCs were applied in an earlier stage of SR-aGVHD, the CR rates
were higher. For example, Le Blanc et al. (42), in their study of a
group of SR grade II-IV patients, described 55% CR and 16% PR.
For that reason, taking into account the side effects of second line
immunosuppression for GVHD and the good safety profile of MSCs
(even in severely affected children), earlier use of MSCs therapy
could be considered for patients with acute SR-GVHD.


Reg